Abstract:Background Checkpoint inhibitors towards cytotoxic T-lymphocyte protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have paved the way for a new frontier of anti-cancer therapies that modulate our pre-existing immune system to fight against malignancies. 4-1BB is a tumor-necrosis superfamily member expressed on NK and T cells, that acts as a co-stimulatory receptor to improve effector/memory responses towards tumors. Early efforts have focused on the generation of agonist antibodies towards 4-1BB that relied on Fc-mediated cross-linking to cluster and induce receptor downstream signaling, but has led to liver- and immune-related toxicities. We have discovered a PD-L1 x 4-1BB bispecific that exhibits conditional agonist activity in the presence of PD-L1 with better safety features. Methods vHH binders to PD-L1 and 4-1BB were generated from immune libraries derived from camelids and selected via yeast display. Antibody screening was carried out by protein-protein interaction analysis and cell-based binding. Target-related activity was confirmed using luciferase reporter assays. Primary immune cells were also tested for T cell activation via the detection of IL-2 and IFNg secretion. PD-L1-mediated 4-1BB activation via cross-bridging was carried out using target cells expressing PD-L1 co-cultured with effector cells. X-ray crystallography was conducted to resolve the binding sites of both the anti-PD-L1 and anti-4-1BB vHHs. Both tumor efficacy and safety assessment were tested in human knockin mice. Results The 4-1BB binder of PM1003 was found to interact with the CRD4 domain of 4-1BB, as determined by X-ray crystallography. Binding to this domain does not affect the binding between 4-1BB and its ligand 4-1BBL. The anti-PD-L1 vHH binds to an epitope on PD-L1 that overlaps with the binding region of PD-1, and is thus effective in disrupting the interaction between PD-1 and PD-L1. Using luciferase reporter assays and primary cell assays we found the PM1003 could activate 4-1BB in the context of PD-L1-mediated cross-bridging. Data from human 4-1BB and PD-L1 knockin mice also showed that PM1003 could effectively control tumor growth without observing any toxicity signals. Conclusions PM1003 is a safe and efficacious bispecific antibody that blocks PD-L1 and concurrently activates 4-1BB receptor. An antibody with mild activity was selected directed against the CRD4 domain of 4-1BB to elicit effective potency while minimizing potential toxicity issues. This was reflected in our results. Thus, PM1003 is a potential next generation therapeutic antibody in the IO space that combines and synergizes two independent signaling pathways to control tumor growth.

The Bispecific Antibody HB-32, Blockade of Both VEGF and DLL4 Shows Potent Anti-Angiogenic Activity in Vitro and Anti-Tumor Activity in Breast Cancer Xenograft Models.

A Humanized Anti-Dll4 Antibody Promotes Dysfunctional Angiogenesis and Inhibits Breast Tumor Growth.

A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities

Mmgz01, an Anti-Dll4 Monoclonal Antibody, Promotes Nonfunctional Vessels and Inhibits Breast Tumor Growth

The Two Novel DLL4-targeting Antibody-Drug Conjugates MvM03 and MGD03 Show Potent Anti-Tumour Activity in Breast Cancer Xenograft Models

Two Engineered Site-Specific Antibody-Drug Conjugates, HLmD4 and HLvM4, Have Potent Therapeutic Activity in Two DLL4-positive Tumour Xenograft Models.

A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin.

Optimized Expression And Characterization Of A Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 And Programmed Death-1 In Pichia Pastoris And Evaluation Of Antitumor Activity In Vivo

Construction of a Novel Bispecific Antibody to Enhance Antitumor Activity Against Lung Cancer.

A bispecific decoy receptor VEGFR-EGFR/Fc binding EGF-like ligands and VEGF shows potent antitumor efficacy

A Novel Bispecific Diabody Targeting Both Vascular Endothelial Growth Factor Receptor 2 and Epidermal Growth Factor Receptor for Enhanced Antitumor Activity

An antibody fragment against human delta-like ligand-4 for inhibition of cell proliferation and neovascularization

Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment

A Human IgG-like Bispecific Antibody Co-targeting Epidermal Growth Factor Receptor and the Vascular Endothelial Growth Factor Receptor 2 for Enhanced Antitumor Activity.

A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy

An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-β with enhanced antitumor efficacies

Bispecific Antibody Simultaneously Targeting PD1 and HER2 Inhibits Tumor Growth Via Direct Tumor Cell Killing in Combination with PD1/PDL1 Blockade and HER2 Inhibition

895 Discovery of a safer 4–1BB agonist by targeting a membrane-proximal epitope combined with bispecific-mediated cross-bridging

Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer

Bispecific gene antibody(Anti-human Bladder Carcinoma/Anti-VEGF) on animal model of bladder carcinoma

A Novel Bispecific Antibody CVL006 Superior to AK112 for Dual Targeting of PD-L1 and VEGF in Cancer Therapy